Real-world study shows positive outcomes for gene therapy in patients with RPE65-IRD

Treatment with voretigene neparvovec (VN, Luxturna) in patients with RPE65-IRD (retinal pigment epithelium 65-inherited retinal dystrophy) shows promising outcomes, according to a real-world study. The retrospective study conducted at a single center included 30 eyes from 19 patients, with a median follow-up of 15 months. The treatment demonstrated stability in...